Summary of current human models for MA4+ B-ALL
| Ontogeny stage . | Cell type . | Phenotype . | Leukemic cooperation with FLT3/RAS* mutants . | Reference . |
|---|---|---|---|---|
| Fetal-HSPC* | NA | — | NA | — |
| Embryonic HSPC | hESC-derived hematopoietic cells | Enhances early hemato-endothelial specification | No | 117 |
| Skew toward endothelial vs hematopoietic fate | ||||
| 118 | ||||
| Neonatal HSPC | CB-derived CD34+ HSPCs | Proliferation coupled to survival advantage | No | 116 |
| Enhanced engraftment and clonogenic potential | ||||
| 119 |
| Ontogeny stage . | Cell type . | Phenotype . | Leukemic cooperation with FLT3/RAS* mutants . | Reference . |
|---|---|---|---|---|
| Fetal-HSPC* | NA | — | NA | — |
| Embryonic HSPC | hESC-derived hematopoietic cells | Enhances early hemato-endothelial specification | No | 117 |
| Skew toward endothelial vs hematopoietic fate | ||||
| 118 | ||||
| Neonatal HSPC | CB-derived CD34+ HSPCs | Proliferation coupled to survival advantage | No | 116 |
| Enhanced engraftment and clonogenic potential | ||||
| 119 |
Unpublished preliminary data.